Industry News
Biotechnology Industry News
Kriya cashes in $270M series C to further finance all-in-one gene therapy biz
Kriya cashes in $270M series C to further finance all-in-one gene therapy biz mbayer Sun, 05/15/2022 - 18:02
mRNA Unlocked: How Technology Convergence Is Driving the Next Wave
mRNA Unlocked: How Technology Convergence Is Driving the Next Wave jfrasor Fri, 05/13/2022 - 12:39
Update: Checkmate details bleak future if $250M Regeneron merger does not close
Update: Checkmate details bleak future if $250M Regeneron merger does not close aarmstrong Fri, 05/13/2022 - 11:16
Adagio still hopes to build omicron offense for lead COVID-19 therapy
Adagio still hopes to build omicron offense for lead COVID-19 therapy aarmstrong Fri, 05/13/2022 - 09:34
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal aarmstrong Fri, 05/13/2022 - 08:54
FDA tags Editas’ thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic
FDA tags Editas' thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic ntaylor Fri, 05/13/2022 - 07:29
Roche’s TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug
Roche's TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug ntaylor Fri, 05/13/2022 - 04:55
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation mbayer Thu, 05/12/2022 - 13:24
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race ntaylor Thu, 05/12/2022 - 08:58
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom ntaylor Thu, 05/12/2022 - 07:47
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data gmasson Wed, 05/11/2022 - 21:55
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results aarmstrong Wed, 05/11/2022 - 15:19
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute ‘false and speculative narrative’ at trial
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute 'false and speculative narrative' at trial gmasson Wed, 05/11/2022 - 13:51
Welcome to new (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal
Welcome to new (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal mbayer Wed, 05/11/2022 - 10:45
Novo Nordisk, Flagship’s forward-thinking partnership aims to treat cardiometabolic, rare diseases
Novo Nordisk, Flagship's forward-thinking partnership aims to treat cardiometabolic, rare diseases gmasson Wed, 05/11/2022 - 10:37
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing deal
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing deal aarmstrong Wed, 05/11/2022 - 10:23
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approval
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approval jwaldron Wed, 05/11/2022 - 09:43
After phase 3 fumble and failed SPAC, Amicus’ Pompe disease drug hits another delay to approval
After phase 3 fumble and failed SPAC, Amicus' Pompe disease drug hits another delay to approval jwaldron Wed, 05/11/2022 - 09:43
Inovio CEO departs, leaving Jacqueline Shea in charge of ‘particularly challenging period’ in the DNA vaccine biotech’s history
Inovio CEO departs, leaving Jacqueline Shea in charge of 'particularly challenging period' in the DNA vaccine biotech's history aarmstrong Wed, 05/11/2022 - 09:30
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies jwaldron Wed, 05/11/2022 - 07:47